🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- G5269C101
- Market Cap
- Mid Cap
- IPO
- 5/24/2018 · $18.00/share
Business: Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s portfolio assets, ARCALYST, vixarelimab, KPL-404, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation.
Company Contact
- CEO
- Sanj K. Patel
- CFO
- Mark Ragosa
- Headquarters
- 100 Hayden Ave, Lexington, MA 02421
- Phone
- 781-431-9100
- Investor Relations
- Rachel Frank · 339-970-9437 · rfrank@kiniksa.com